

Pharma SUG SDE Japan 2023

Innovative Approaches for Clinical Trial Data Analysis and RWD Analysis : SAS[®] Health Clinical Acceleration SAS[®] Health Cohort Builder SAS Institute Japan Toshiaki Habu• William Kuan



SAS[®] Life Science Analytics Framework (LSAF) SAS[®] Health Clinical Acceleration (HCA)

S.sas

History of SDD/LSAF/HCA

Previous Solution

SAS ® Drug Development (2005~2014)

SAS execution environment for regulatory requirements

- SAS9 based
- Java-based
- On-premise provision (Cloud provision in the latter half)
- Programming
- Comply with regulatory requirements (Part 11, etc.)
- Workspace functionality

Current Solution

SAS ® Life Science Analytics Framework (2015~)

Managed Cloud Service

- SAS9 based
- HTML5
- Provided in Cloud

- Workflow Function
- Enhanced Macro API

SAS® Health Clinical Acceleration (2023 \sim)

Move to Viya-based from SAS9-based

- Engine modernization (based on Viya)
- Modularization of functions: further expansion planned

For about 18 years since SDD launch, it has been used by many companies, including global pharmaceutical companies, as a repository and SAS execution environment that complies with FDA CFR 21 Part 11 and other regulatory requirements.

$\bullet \bullet \bullet \bullet \bullet \bullet \bullet$



SAS Viya

Provides the entire suite of functions and software necessary to promote data utilization on a single platform



SAS[®] Life Science Analytics Framework (LSAF) Overview



S.sas

Flexible Integration Capabilities





Support collaborations within the organization and with external partners

Each user can connect to the LSAF server managed by SAS via https from a browser to develop and run programs and exchange SAS data sets and other files with other personnel, regions, and departments.



Overview of LSAF (1/2)

LSAF is a solution that provides repository functions for clinical data and data standards, as well as program development and execution functions such as statistical analysis, in a secure cloud format for life science companies.

- Server maintained and managed by SAS. Available via web browser (https)
 - Provided as a cloud service, reducing companies' burden on system construction, maintenance, and validation.
 - Web-based, so it can be used without concern for the PC environment of each user.
- Provides a clinical data repository (CDR) and statistical computing environment.
 - No restrictions on supported file formats, including SAS data sets, programs, and other SAS-related files, as well as CSV, Word, Excel, PDF, and other formats.
 - Groups and roles (combinations of permission and privileges required for each role, such as programmer, medical writer, etc.) can be freely defined, and security can be efficiently configured in terms of access and privileges.
 - Provides a personal area (development area) and a shared area (production area) that can be used for SAS program development and production execution.

Key Point!!

Provides regulatory compliance capabilities

- Audit trails, implementation of version control, and traceability functions enable efficient electronic recording/electronic signature and GxP compliance.
- FDA 21 CFR Part 11 compliant

$\bullet \bullet \bullet \bullet \bullet \bullet \bullet \bullet$





Overview of LSAF (2/2)

Easy integration with other applications.

- Extensive experience with EDC integration such as Medidata Rave and InForm, and Pinnacle 21 Enterprise/Community for the purpose of improving operational efficiency and security through automation.
- Easy deployment of machine learning, RWD, etc. by leveraging SAS Viya, Python and R, etc.

Workflow Functions

- Workflow functionality improves operational efficiency and visualizes progress.
- Comply with industry standards (Business Process Model and Notation 2.0) for workflow design enables user-centered operations.

SAS® Health Clinical Acceleration

S.sas

SAS® Health Clinical Acceleration at a Glance

Overview

SAS[®] Health Clinical Acceleration (HCA) provides a modular, open, cloudnative content repository for managing, analyzing, reporting, and reviewing clinical research information. It is the <u>successor to LSAF on Viya</u>.

SAS HCA improves the way people work in a qualified environment and enables life science organizations to maintain data integrity, make informed business decisions, effectively assess the safety and efficacy of research compounds, collaborate across trials, phases, therapeutic areas, and ultimately streamline the drug development process and accelerate their submissions to the FDA.

0 2 2 2 2 2	More Recent ador 1 ador 2 ador 3 ador 5 ador 5						Activity Oriented Jan J, HEL352946045456, 14/1 14/1 Oriented Jan J, HEL352946045456, 14/1 14/1 Oriented Jan J, HEL352940045456, 14/1 14/1 Oriented Data 21/2002, 212/40, 2017 DAta 3/1 Oriented Data 3/2002, 212/40, 2017 DAta 3/1 14/1 Oriented Data 3.2002, 212/40, 2017 DAta 3/1 14/1		445. 445. 445. 445.		VerA	A	
Rep	ostory + Bale	ρ β			•	8	3 me •	× 101 - 8	Managa +	000	0		
	7,00	Name		4	See	Modified By	Oute Modified	Veslor	Sinte 7			1	
	Brie	Baladiet.	Name 11		24/278	Karen Chaney	Dei 4, 2022, 11.43 AM GMT 05:00		(Q Saynel	(d Loded)	٠	1	
	@ File	Baliziet.	Name 10		410 lightes	Karen Chaney	Dec 1, 2022, 10:03 AM GMT-05:00		Osperat			1	
	C Folder	Baladies	Name 22			Mushit Agithtis	Nov 25, 2022, 09:11 AM-GMT-65:00				٥	4	
	Cfolder	faisfer.	Name 00			Shari Forvendel	Nov 22, 2022, 08:21 AM CMT-05:00				۰.	1	
	(2) File	Buisdes.	Name 27		400 bytes	Mushit Apitnia	Nov 20, 2022, 05:31 PM GMT 05:00	30	(2 Same		۰.	1.	
	B Context	fairdet	Name 26			Muchit Agents	Nov 19, 2022, 63:19 PM GMT 05:00		G-Dovel		ġ.	11	
	@rie	Balades	Name 25		450 lights	Shari Forvendel	Nov 15, 2022, 09:03 AM CMT 05:00				¢.	1	
	Enfolder	Subdet.	Name 24			MachitApress	Nov 11, 2022, 08:11 AM-CMT-65:00				٥	1	
	Efolder	Sublet.	Name 32			Shari Forvendel	Nov 9, 2022, 11:08 AM GMT-05:00				۵	1	
	D 10+	Balader.	Name 82		764 bytes	Mucuhit Apitmia	Nov 3. 2022, 08:11 AM GMT 05:00		(D Signed			1.	
	Q 75e	block.	Name 21		810 bytes	Mucahit Agitthia	Sept 23, 2022, 07:23 AM GMT-05:00		(\$1000	0	φ.	1	
	() Pile	Cammo	n.fuix.Name21		471 bytes	Shat Porvendel	Sept 15, 2022, 03:45 PM GMT-05:00				9	1	
	Efolder	Canna	Mix.Nete26			Shat Forvendel	Aug 18, 2022, 02:35 PM GMT 05						_
	Efolder	Canno	n. Ruix, Name 25			MichielApithia	Aug 1, 2022, 01 55 PM GMT 05:0	ES pa	ormatic	Cancers	hudi	h Recording the	
	😂 Folder	Commo	n.Reis,Name.M			Shari Forvendel	3-4/4, 2022, 12:05 PM GMT-05:0				,	,,	
	Efolder	Conno	n,Reis,Named3			Shari Forvendel	June 25, 2022, 12:05 PM GMT-05	Test 1 is	a study o	n pancreati	ic ca	ancer patients. In th	8 57.
	⊡ Folder	Commo	n.Net.Netted2			Muchit Apitnia	June 25, 2022, 12:05 PM GMT-05						
	Clinkler.	Commo	n. Bala, Name 21			Mushit Agittis	June 25, 2022, 12:05 PM CMT.01	1.011 00.00	neu. Dec	011001 3,20			

Platform: Viya 4

Value Propositions:

- Faster Clinical Analysis and Submission Improved UX
- Regulated Clinical Trial Operations Single Source of Truth
- Viya Enabled Programming, Analytics & Automation
- Open Integration Bring your own tool

Personas: Head of IT, Head of Biostats, Study Lead, Biostatistician, Administrator, Programmer, Content Manager, Auditor/Regulator, IT Administrator

Upcoming Features in MVP:

- Repository
 - Groups & Permissions
 - Roles & Privileges
 - Version Control
 - Electronic Signatures
 - Recycle Bin
 - Search
- Ownership Administration
- Audit History
- Action Status



The Future of Efficient, Data-Driven Clinical Trials

with SAS Viya



SAS[®] Health Cohort Builder



S.sas

Challenges in dealing with Real World Data

The amount of data to be processed is so large that SAS frozen (or appears to be frozen). In addition, the data wrangling and data cleansing steps took up my whole day.

There are concerns about the ability of our analytics platform on handling yearly increasing data volumes and data sources.

Data extraction is not feasible without skilled specialists.



Challenges in dealing with Real World Data

SAS Viya technology accelerates data processing

Highly scalable analytics platform and easy to add additional computing nodes (processing servers), etc.

This system has a common data model and can handle data from any data source via GUI



Reimagining health analytics in the cloud.



Cohort Builder

Easily and confidently build patient subsets within a unified analytics platform

• Interactive, drag-and-drop capability to support complex cohort queries with temporal relationships - no coding required



• •



Reimagining health analytics in the cloud.



Cohort Builder

Easily and confidently build patient subsets within a unified analytics platform

- Interactive, drag-and-drop capability to support complex cohort queries with temporal relationships – no coding required
- Explore cohort characteristics and the effect of inclusion / exclusion criteria on patient populations





Reimagining health analytics in the cloud.



Cohort Builder

Easily and confidently build patient subsets within a unified analytics platform

- Interactive, drag-and-drop capability to support complex cohort queries with temporal relationships – no coding required
- Explore cohort characteristics and the effect of inclusion / exclusion criteria on patient populations
- Utilize health care ontologies for selecting code sets to include within cohort criteria







Reimagining health analytics in the cloud.



Cohort Builder

Easily and confidently build patient subsets within a unified analytics platform

- Interactive, drag-and-drop capability to support complex cohort queries with temporal relationships no coding required
- Explore cohort characteristics and the effect of inclusion / exclusion criteria on patient populations
- Utilize health care ontologies for selecting code sets to include within cohort criteria
- Leverage and extend your own analytic assets





Reimagining health analytics in the cloud.



Cohort Builder

Easily and confidently build patient subsets within a unified analytics platform

- Interactive, drag-and-drop capability to support complex cohort queries with temporal relationships - no coding required
- Explore cohort characteristics and the effect of inclusion / exclusion criteria on patient populations
- Utilize health care ontologies for selecting code sets to include within cohort criteria
- Leverage and extend your own analytic assets
- Gain fast, easy access to advanced health analytics and visualizations





Overview of Process



$\bullet \bullet \bullet \bullet \bullet \bullet \bullet$



Project Management



$\bullet \bullet \bullet \bullet \bullet \bullet \bullet \bullet$

Data Source Selection



- Map source data to standard format once
- Data load performs validation and profiling

$\bullet \bullet \bullet \bullet \bullet \bullet \bullet$



Define Inclusion and Exclusion Criteria

	SAS® Health: Cohort Builder - Build Cohorts	a 2 🐨
Home → I≡Project Project: Stroke in Afib Patients	Define Cohort Add Variables Build Analysis Cohort: Data source: 800K_ICD10 N- Cohort count: n=135,619 Cohort count: N=10,019 Cohort count: Cohort count:	E C E :
 Concepts ♥ Index Events ♥ Saved D Filter > Demographics > Diagnosis Codes > Diagnosis Related Groups > Observations > Procedures > Visits Enrollment 	 Aug 2008 Nov 2009 Feb 2011 May 2012 Jul2013 Index Event: Afib Dx And OR NOT > b b f f f f f f f f f f f f f f f f f	Attrition
	 No coding required Complex criteria supported Share/reuse criteria 	

$\bullet \bullet \bullet \bullet \bullet \bullet \bullet \bullet$

Company Confidential – For Internal Use Only Copyright © SAS Institute Inc. All rights reserved. wsas

Define Inclusion and Exclusion Criteria

=	SAS® Health: Cohort Builder - Build Cohorts	Q 2 🐨
Home → ≔ Project Project: Stroke in Afib Patients	Define Cohort Add Variables Build Analysis Data source: Cohort Cohort count Cohort count Cohort count	圖 ピ 囲 : 800K_ICD10 N=711,479 ♀ t: n=135,619
🐞 Concepts 🖷 Index Events 🖲 Saved		Attrition 📃 🖽
Ethnicity	> May 2007 Aug 2008 Neg 2000 Eab 2011 May 2012	Attrition () (O Counts
Gender Code	May 2007 Aug 2006 Nov 2007 Peb 2011 May 2012	30/2013
GFR test	> Index Event Afib Dx	Total Population 100%
GI Bleed		Apply Study Period 90%
HDATC		Арру
History of Obstructive CVD	> 📀 🗌 Age at Index Date >= 🔹 40	Afib Dx 46%
HTN	> Ø 🗌 Gender Code is "Male"	Age ge 40 45%
Hyperlipidemia		
Hypert3	> O Hypertension	Males 19%
Hypertension	V 🕗 🗌 « » NSAIDS	
Hyptension	∨ Relationships ⊚	
10-1 C	Time to Hypertension: On or after: Value: 0	
	NSAIDS On or after: + Add cor	nstraint 🔻
1000-00	Before:	
	V Codes On on before.	
	After:	
	Code Type Vocabulary	
	50043013701 Alti minimizion y oran NA NDC 52904048602 Pain Relief Anti inflam RX NDC	
Stroke	□ 70529011801 Cortaren Corticosteroi RX ND	
StrokeSCA	□ 70529011201 Neuromaquel Neurom RX ND	
T2DM	✓ Occurrences	ting up a time series
Test	Number of occurrences: >= • 1	eng ap a ente series
Testing for CVD		

$\bullet \bullet \bullet \bullet \bullet \bullet \bullet \bullet$

NSE

E		SAS® Health: Cohort Builder - Build Cohorts	۹ 2 💓
ld Home → I≡Project Project: Stroke in Afib Patients	Define Cohort Add Variabl	les Cohort: Data source: 80 Cohort count: n	© C' Ⅲ : =135,619
P Filter Etimicity Gender Code GFR test GI Bleed HbA1c HBP History of Obstructive CVD HTN Hyperlipidemia Hypert3 Hypertension	Antiarrhythmic Anticagulants Cardioversion Charlson Risk Factor Set	Type 또 Custom Variable - Prescriptions 또 Custom Variable - Prescriptions 또 Custom Variable - Procedures 또 Custom Variable - Procedures Risk Factor Set	Results
Stroke StrokeSCA T2DM Test Testing for CVD Valsartan Victoza ZIP Code		Predefined itemsDefine and share	s such as risk scores, etc. e others





Utilization of Analysis Templates (pre-created template selection)



$\bullet \bullet \bullet \bullet \bullet \bullet \bullet \bullet$



Adjustment of Output Variables

≡		SAS® Health: Cohort Builder - Build Cohorts		a 2 🐨
a Home > I≡ Project roject: Stroke in Afib Patients	Define Cohort Add Variab	les Build Analysis	Cohort: Data source: 800K_ICD10 N=711,479 🔾 Cohort count: n=135,619	∎ c* ₽ :
≅ DemoPurpose_BinaryRegressionPredictiveN	Nodel			Close
E Information Q Execution				
ጵ 🥏 Data Study Definition Incidence Rates Build Model E	xport	Log Results Output Data		
Prediction Model Setting Target outcome variable (maximum of two variables):		AV_STROKE_FLG_LRModel.html	Logistic Regression	^
Stroke Target variable value: 1			Model Information Data Source C8_AV_STROKE_FLG Response Variable AV_STROKE_FLG Distribution Binary	
		-	Link Function Logit Optimization Technique Newton-Raphson with Ridging	
Predictors Input variables: Available items (6):	Selected items (7):		Number of Ubservations Description Total Training Validation Number of Observations Read 135619 101714 33905 Number of Observations Used 135619 101714 33905	
Stroke AV_STROKE_FLG (2)	₽ Filter		Response Profile Ordered AV_STROKE_FLG Frequency Training Validation	
Census State CENSUS_STATE (10)	Antiarrhythmic AV_ANTIARRHYTHMICS_FLG (2)		1 0 111092 83214 27876 2 1 24527 18500 6027	
Race Code RACE_CD (4)	Anticoagulants AV_ANTICOAGULANTS_FLG (2)		Probability modeled is AV_STROKE_FLG = 1.	
age_at_study_end age_at_study_end (64)	Cardioversion AV_CARDIOVERSION_FLG (2)		Selection Method Stepwise Select Criterion SBC	•





Visualization of Analysis Outputs (VA function)

ACS End2End (Life Sciences RWE Demo) The selections The sele	E SAS® Visual Analytics - Expl	ire and Visualize	۹ 🛛 🐨
Texte Date Date Date Date Date Date Date Da	ACS End2End (Life S	2 10 つ ? : 1	
<pre>Fire: Notestime State State State State State State State State</pre>	Stroke Death Quartiles by County 🚦 Demographics Baseline Characteristics Frequency of Stroke Anticoagulants Switching Patterns Treatme	ent Patterns Cluster LOS, Age, Cost Logistic Regression Gradient Boosting Decision Tree N	Neural Network Model Co 🗲 🔲
Tree Dearts Quartiles by County, CDC 2016	Filters: No selections		
Stroke Deaths Quartiles by County, CDC 2015	State •		
isual tools for exploration, analytics and Al/ML	Stroke Deaths Quartiles by County, CDC 2016		
uartiles	/isual tools for exploration analytics and AI/MI		
	risual tools for exploration, analytics and Al/IVIL	Juartiles	

• Coding interfaces for SAS and open source

()

$\bullet \bullet \bullet \bullet \bullet \bullet \bullet$

•



Utilization of analysis results. Automatic analysis function for output (AI function)

=	SAS® Visual Analytics -	lytics - Explore and Visualize						
1	ACS End2End (Life S	ciences RWE Demo)	x* I ∽ ⊂ I I					
Baseline Automated Explanation : Logistic Regression	Decision Tree Neural Network Gradient Boosting	Model Comparison						
Relaxed Criteria		Stringent Criteria						
What are the characteristics of MI or Cardiac	Cath? 0 1	What are the characteristics of MI or Cardiac	Cath? 0 1					
MI or Cardiac Cath has a 53.40% chance (7.8K of 15K) of common MI or Cardiac Cath value.	being 1. It's the most	MI or Cardiac Cath has a 53.44% chance (4.4K of 8.2K) of common MI or Cardiac Cath value.	being 1. It's the most					
What factors are most related to MI or Cardiac Cath?	What is the relationship between MI or Cardiac Cath and age_at_index_dt?	What factors are most related to MI or Cardiac Cath?	What is the relationship between MI or Cardiac Cath and age_at_index_dt?					
Hyperlipidemia	1,500	Hyperlipidemia	1,000					
age_at_index_dt	1,000	age_at_index_dt	800 600 400					
What are the groups based on age_at_index_dt by the chance of MI or	0 22.5 42.5 62.5 82.5 102.5	What are the groups based on age_at_index_dt by the chance of MI or Condiae Cathering 12	200 0 22.5 42.5 62.5 82.5 102.5					
	age_at_index_dt		age_at_index_dt					
< High Low >		< High Low >	1 0					
64.56% hage_at_index_atis less than 30, then MI or Cardiac Cath has a 64.56% chance (51 out of 79 cases) of being 1.	The average age_at_index_dt when MI or Cardiac Cath is 1 is 73, with a minimum of 24 and a maximum of 101. The average age_at_index_dt when MI or Cardiac Cath is 0 is 74, with a minimum of 24 and a maximum of 101. Average age_at_index_dt is 73, and it ranges from 24 to	66.04% Trage_at_index_dt is less than 30, then MI or Cardiac Cath has a 66.04% chance (35 out of 53 cases) of being 1.	The average age_at_index_dt when MI or Cardiac Cath is 1 is 72, with a minimum of 25 and a maximum of 101. The average age_at_index_dt when MI or Cardiac Cath is 0 is 73, with a minimum of 24 and a maximum of 101. Average age_at_index_dt is 73, and it ranges from 24 to					
63.89% if hyperlipidemia is 0,	101.	62.14% IT Hyperlipidemia is 0,	101.					
	Company Confidential	- For Internal lice Only	<u>S</u> sa					

Utilization of analysis results. Automatic analysis function for output (AI function)







SAS® Clinical Enrollment Simulation (Overview)



S.sas

Most clinical trials fail to meet enrollment timelines.



Approximately **90%** of clinical trials do not • meet patient enrollment targets on time.



Every day of delay in clinical trial completion can cost sponsors **millions**.



Missing clinical subject recruitment milestones can **negatively impact the reputation** of a Clinical Research Organization (CRO).



Traditional Approach to Projecting Enrollment

Using Excel to Calculate Future



- Typically work backwards from goal
- Unrealistic assumptions from static estimates with no variability in inputs
- Doesn't account for enrollment decays over time
- Approximately 20% of sites never enroll anyone
- Costs are not accounted for
- Difficult to track "what if" scenarios



SAS Helps You Optimize Study Start-up and Progress

Identify the right sites and optimal clinical strategy.



Ensure clinical trials get up and running quickly, efficiently and in keeping with your milestones for completion.

> Company Confidential – For In Copyright © SAS Institute Inc. All rig



Optimize Study Start-up and Progress

How SAS Delivers



- Powerful simulation analytics to quickly obtain insights
- Simulate different enrollment scenarios, costs and global regulatory timelines
- Better insights to inform decision making and trial strategy
- Easy data integration and real-time visualizations





Our Approach

Discrete Event Simulation Yields Better Enrollment Projections



\$

Develop Enrollment Projections

- Enter all assumptions and simulate multiple replications of the enrollment
- Show likelihood to achieve specific targets

Capture Variability

- Get a better understanding of likely outcomes
- Produce more accurate predictions for achieving targets

Realis

Realistic Enrollment Estimates

 Obtain peak and lower enrolment period windows to account for enrolment decay



Include Costs

- Include startup costs for countries and sites and per-patient costs
- See the cost impact of different
- scenarios



Scenario Tracking

- Compare and track multiple scenarios with varying inputs
- Test the impact of factors such as adding new sites and/or countries or changing baseline assumptions



Simulating Enrollment output例

Calculate Probabilities of Success

			Success Rate Range		
Target Name	Target Date	Success Rate	Best	Median	Worst
Dates					
First Country Approval	Not provided	N/A	July 26, 2022	August 6, 2022	August 25, 2022
First Site Startup	August 31, 2022	46%	August 19, 2022	September 1, 2022	September 21, 2022
First Subject Screening	Not provided	N/A	August 23, 2022	September 5, 2022	September 25, 2022
First Subject Enrollment	September 15, 2022	89%	August 23, 2022	September 6, 2022	September 25, 2022
First Subject's First Visit	Not provided	N/A	August 30, 2022	September 13, 2022	October 2, 2022
First Subject's Last Visit	Not provided	N/A	February 19, 2023	March 5, 2023	March 24, 2023
End of Enrollment	December 31, 2023	69%	November 2, 2023	December 1, 2023	March 25, 2024
Last Subject's First Visit	Not provided	N/A	November 9, 2023	December 8, 2023	April 1, 2024
Last Subject's Last Visit	Not provided	N/A	April 30, 2024	May 29, 2024	September 21, 2024
Cost	Target Cost	Success Rate	Best	Median	Worst
Estimated Cost	\$2,900,000	61%	\$2,802,916	\$2,885,824	\$2,974,546





Site Setup Values

Hole Sites - Site: Yan Place Medical Center Bites Beside Control State Control Site Name** Cested: Control Cested: Control Cested: Control Cested: Control Description: Description: Cested: Control Description: Cested: Control Description: Cested: Statup Trine(Days) Statu			SAS® C	linical Enrollment Simulation Clo	ud				12	C
Social Status Subjects Social Status	Sites > Site: Twin Pines Medica	l Center							(
LEMINTs Delais Sudia Name: • • • • • • • • • • • • • • • • • • •	🖪 Twin Pines Medic	al Center								
Countries Name:* Imme Medical Context Sites Description: Imme Medical Context Created: // December 09, 2022 at 09:12:23 AM Last modified: // December 09, 2022 at 09:12:23 AM Country: United States Number of available sites:* 0 1 Therapeutic Area* Startup Time (Days) Imme Startup Time (Days) Imme Startup Time (Days) Imme Startup Time (Days) Startup Time (Days) Startup Time (Days) Imme Startup Time (Days) <td>Details</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Details									
Sites Description: Created: Description: Created:	Name: *	Twin Pines Medical Center								
Created: / December 09, 2022 at 09:12:23 AM Last modified: / December 09, 2022 at 09:12:23 AM Country: United States Number of available sites: • 0 Image: Image	Description:									
Last modified:	Created:	/ December 09, 2022 at 09:12:23	AM							
Country: United States Number of available sites: * 0 1 Therapeutic Areas Startup Cost* 0 Best Case * Therapeutic Area* Startup Time (Days) 0 Startup Time (Days) 0 Startup T	Last modified:	/ December 09, 2022 at 09:12:23	AM							
Number of available sites:* 0 1 Therapeutic Areas Startup Cost* 0 Best Case * Typical * Startup Time (Days) 0 Vorst Case * Startup Success Probability of E Months High R High Recruitment * Subjects per Month Cow Recruitment * Subjects per M	Country:	United States								
Therapeutic Areas Startup Cost* © Best Case * Startup Time (Days) © Typical * Startup Time (Days) © Worst Case * Startup Time (Days) ©	Number of available sites: * Ø	1								
Therapeutic Areas Startup Cost* © Best Case * Startup Time (Days) © Typical * Startup Time (Days) © Start										
Image: Therapeutic Area* Startup Cost* ① Best Case* C	Therapeutic Areas								+	1
Cardiology/carc \$7,000 21 30 45 99% 2% 9 6 4	Therapeutic Area *	Startup Cost* Best Case * Startup Time (Days)	Typical * Startup Time (Days)	Worst Case * Startup Time (Days)	Startup Success	Probability of E	Months High R	High Recruitment * Subjects per Month	Low Recruitment * Subjects per Month	:
	Cardiology/carc	\$7,000 21	30	45	99%	2%	9	6	4	
		Sites > Site: Twin Pines Medica Twin Pines Medica Details Name:* Description: Created: Last modified: Country: Number of available sites:* Therapeutic Areas Therapeutic Areas Therapeutic Areas Cardiology/carc	Sites → Site: Twin Pines Medical Center	Sites → Site: Twin Pines Medical Center Sites → Site: Twin Pines Medical Center Details Name:	Sites → Site: Twin Pines Medical Center Sites → Site: Twin Pines Medical Center Details Name:* Ivin Pines Medical Center Description: Created: / December 09, 2022 at 09:12:23 AM Last modified: / December 09, 2022 at 09:12:23 AM Country: United States Number of available sites:* Image: Imag	Sites > Site: Twin Pines Medical Center Sites > Site: Twin Pines Medical Center Details Name: Vame: Vame:	SAS® Cloud Encolment Simulation Cloud Site: Twin Pines Medical Center Details Name: * Twin Pines Medical Center Description: Created: / December 09, 2022 at 09:12:23 AM Last modified: / December 09, 2022 at 09:12:23 AM Country: United States Number of available stee: * 0 Imerapeutic Areas Imerapeutic Areas Startup Cost* 0 Startup Time (Days) 0 Startup Time	Site: Site: Twin Pines Medical Center Set Site: Twin Pines Medical Center Details Name:	Site: visite: twin Pines Medical Center Site: visite: twin Pines Medical Center Details Name: Venter for Note Medical Center Cested:	State: with Prices Medical Center Cental Details Nume: * om Prices Medical Center Description:

$\bullet \bullet \bullet \bullet \bullet \bullet \bullet \bullet$

Setting of simulation parameters for the entire clinical trial

≡							SAS® Clinical Enrollment Simulat	ion Cloud				
	Home BUILDER Scenarios ELEMENTS	Scenarios E Ca Scena	s → Scenario: Card rd10 13 with rio and Study Detai	lio 13 with 10 US TU US Site ils Study Disc	Sites S ontinuation Estimates Vi	sit Schedule Additional Ta	rgets Countries and Sites					ô 🛧 Ø
€	Studies Countries	v Cou	ntry Settings									+
	Sites		Name	S	tartup Cost * 💿	Best Case * Startup Time (Days)	Typical * Startup Time (Days)	Worst Case * Startup Time (Days)	Startup Succ	ess Probabi	Concurrent Sites Possible*	Screen Failure Rate
			United States		\$12,000	24	30	60	100%		100	22%
		v Ur s	ined states Site: ite Chenango Me	Number of Sit	es* Startup Cost* @	Best Case * Startup Time (Days)	Typical * Startup Time (Days)	Worst Case * Startup Time (Days)	Startup Success	Probability of E	Months High R	High Recruitment Subjects per Mont
		C	Chenango Me	1	\$5,500	14	21	30	99%	2%	8	10
		C	Derry Medical	1	\$4,500	21	30	45	95%	2%	8	9
		L	assen Gener	1	\$6,000	21	30	45	97%	2%	9	8
		S	acred Heart	1	\$5,000	21	30	45	99%	5%	6	10
		S	hasta Region	1	\$5,500	21	30	45	99%	2%	6	9
		s	t Eligus Hosp	1	\$7,500	21	30	45	99%	2%	8	7
		т	ower Medica	1	\$6,550	21	30	45	99%	2%	7	6
		Т	win Pines Me	1	\$7,000	21	30	45	99%	2%	9	6
		v	Vestern Regi	1	\$8,000	21	30	45	99%	2%	5	8
		v	Vexler Medic	1	\$4,250	21	30	45	99%	2%	8	8
									-			

$\bullet \bullet \bullet \bullet \bullet \bullet \bullet$

Simulation Result Screen

=			SAS® Clinical Enrollment Simula	tion Cloud		12	C
Home BUILDER	Scenarios → Scenario: Cardio 13 Baseline → Res	ults					F
Scenarios — ELEMENTS	🕞 Cardio 13 Baseline Results						
👗 Studies	Projected Enrollment Targets and Overall R	Country and Site Metrics					
Gountries	Targets (all optional) Overall Results						
🗄 Sites				Success Rate Range			
	Target Name	Target Date	Success Rate	Best	Median	Worst	
	Dates						
	First Country Approval	Not provided	N/A	July 25, 2022	August 8, 2022	August 24, 2022	
	First Site Startup	August 31, 2022	59%	August 14, 2022	August 29, 2022	September 20, 2022	
	First Subject Screening	Not provided	N/A	August 18, 2022	September 2, 2022	September 24, 2022	
	First Subject Enrollment	September 15, 2022	91%	August 18, 2022	September 2, 2022	September 24, 2022	
	First Subject's First Visit	Not provided	N/A	August 25, 2022	September 9, 2022	October 1, 2022	
	First Subject's Last Visit	Not provided	N/A	February 14, 2023	March 2, 2023	March 25, 2023	
	End of Enrollment	December 31, 2023	0%	April 9, 2024	May 11, 2024	April 19, 2025	
	Last Subject's First Visit	Not provided	N/A	April 16, 2024	May 18, 2024	April 26, 2025	
	Last Subject's Last Visit	Not provided	N/A	October 6, 2024	November 7, 2024	October 16, 2025	
	Cost	Target Cost	Success Rate	Best	Median	Worst	
	Estimated Cost	\$2,900,000	98%	\$2,694,754	\$2,814,936	\$2,927,417	

• • • • • • •



Simulation Result Screen





 $\bullet \bullet \bullet \bullet \bullet \bullet \bullet$

Simulation Result Screen Recruitment Period



.



Thank you!!

 Today's presentation may seem to be a bit busy, as we have explained several products in a short time. If you are interested, please feel free to contact us.

• <u>Contact :</u>

SAS Japan Consulting Service Supervisory Division Life Science Team Toshiaki Habu

Mail: toshiaki.habu@sas.com

